74 related articles for article (PubMed ID: 10720839)
1. Isolated hyperthermic liver perfusion with high dose tumor necrosis factor alpha in pigs: an experimental study in preparation of clinical Use.
Lang H; Thyen A; Nadalin S; Frerker M; Moreno L; Flemming P; Martin M; Oldhafer KJ; Raab R
Eur Surg Res; 2000; 32(1):1-10. PubMed ID: 10720839
[TBL] [Abstract][Full Text] [Related]
2. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
[TBL] [Abstract][Full Text] [Related]
3. A porcine model for investigation of hyperthermic isolated liver perfusion.
Lang H; Nadalin S; Thyen A; Moreno L; Shehata SR; Schüttler W; Oldhafer KJ
J Invest Surg; 1998; 11(6):401-8. PubMed ID: 9895114
[TBL] [Abstract][Full Text] [Related]
4. True versus mild hyperthermia during isolated hepatic perfusion: effects on melphalan pharmacokinetics and liver function.
Pilati P; Mocellin S; Rossi CR; Ori C; Innocente F; Scalerta R; Ceccherini M; Da Pian PP; Nitti D; Lise M
World J Surg; 2004 Aug; 28(8):775-81. PubMed ID: 15457357
[TBL] [Abstract][Full Text] [Related]
5. Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan.
Borel Rinkes IH; de Vries MR; Jonker AM; Swaak TJ; Hack CE; Nooyen PT; Wiggers T; Eggermont AM
Br J Cancer; 1997; 75(10):1447-53. PubMed ID: 9166936
[TBL] [Abstract][Full Text] [Related]
6. Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials.
Pogrebniak HW; Witt CJ; Terrill R; Kranda K; Travis WD; Rosenberg SA; Pass HI
Ann Thorac Surg; 1994 Jun; 57(6):1477-83. PubMed ID: 8010790
[TBL] [Abstract][Full Text] [Related]
7. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system.
Zwaveling JH; Maring JK; Mulder AB; Bom VJ; van Ginkel RJ; Schraffordt Koops H; Girbes AR; Hoekstra HJ; van der Meer J
Cancer Res; 1996 Sep; 56(17):3948-53. PubMed ID: 8752162
[TBL] [Abstract][Full Text] [Related]
8. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan.
Lindnér P; Fjälling M; Hafström L; Kierulff-Nielsen H; Mattsson J; Scherstén T; Rizell M; Naredi P
Eur J Surg Oncol; 1999 Apr; 25(2):179-85. PubMed ID: 10218462
[TBL] [Abstract][Full Text] [Related]
9. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
[TBL] [Abstract][Full Text] [Related]
10. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO).
Di Filippo F; Giacomini P; Rossi CR; Santinami M; Garinei R; Anzà M; Deraco M; Botti C; Perri P; Cavaliere F; Di Angelo P; Sofra C; Sperduti I; Pasqualoni R; Di Filippo S; Corrias F; Armenti A; Ferraresi V
In Vivo; 2009; 23(2):363-7. PubMed ID: 19414428
[TBL] [Abstract][Full Text] [Related]
12. Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: encouraging results of a phase II study.
Bonvalot S; de Baere T; Mendiboure J; Paci A; Farace F; Drouard-Troalen L; Bonnet L; Hakime A; Bonniaud G; Raynard B; Israel P; Le Cesne A; Eggermont AM; Laplanche A; Muret J
Ann Surg; 2012 Feb; 255(2):281-6. PubMed ID: 22241290
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of isolated hepatic perfusion with high dose tumor necrosis factor in rat model.
Nakamoto T; Inagawa H; Takagi K; Tashiro K; Yoshimura H; Nishizawa T; Honda T; Kanou J; Muto Y; Amm E; Soma G
Anticancer Res; 2000; 20(1C):619-22. PubMed ID: 10769705
[TBL] [Abstract][Full Text] [Related]
14. [Experimental study on TNF-alpha linked percutaneous isolated hepatic chemoperfusion (PIHP)].
Kusunoki N; Ku Y; Kuroda Y
Gan To Kagaku Ryoho; 1998 Jul; 25(9):1278-80. PubMed ID: 9703807
[TBL] [Abstract][Full Text] [Related]
15. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.
Fraker DL; Alexander HR; Andrich M; Rosenberg SA
J Clin Oncol; 1996 Feb; 14(2):479-89. PubMed ID: 8636761
[TBL] [Abstract][Full Text] [Related]
16. The effect of U-74389G on liver recovery after acute liver ischemia-reperfusion injury in a swine model.
Tsaroucha AK; Papalois A; Vernadakis S; Adamopoulos S; Papadopoulos K; Lambropoulou M; Constadinidis T; Kyriazi A; Papadopoulos N; Simopoulos C
J Surg Res; 2009 Jan; 151(1):10-4. PubMed ID: 18468628
[TBL] [Abstract][Full Text] [Related]
17. TNF-alpha levels in patients with malignant tumors after hyperthermic isolated regional perfusion.
Aksaz E; Erdem E; Erdem D; Unal AM
J Exp Clin Cancer Res; 2002 Dec; 21(4):489-93. PubMed ID: 12636094
[TBL] [Abstract][Full Text] [Related]
18. Hyperthermic isolated hepatic perfusion for the treatment of unresectable cancers confined to the liver.
Carroll NM; Alexander HR
J Surg Oncol; 2002 May; 80(1):64-5; author reply 66-7. PubMed ID: 11967911
[No Abstract] [Full Text] [Related]
19. Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas.
Rossi CR; Mocellin S; Pilati P; Foletto M; Campana L; Quintieri L; De Salvo GL; Lise M
Ann Surg Oncol; 2005 May; 12(5):398-405. PubMed ID: 15915374
[TBL] [Abstract][Full Text] [Related]
20. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
Kettelhack C; Hohenberger P; Schlag PM
Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
